Journal
WORLD JOURNAL OF PSYCHIATRY
Volume 1, Issue 1, Pages 8-18Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5498/wjp.v1.i1.8
Keywords
Alzheimer's disease; Biomarker; Blood; Ce-rebrospinal fluid; Dementia; Plasma
Categories
Funding
- Austrian Science Fund FWF [L 429] Funding Source: Medline
- Austrian Science Fund (FWF) [L 429] Funding Source: researchfish
Ask authors/readers for more resources
Due to an ever aging society and growing prevalence of Alzheimer's disease (AD), the challenge to meet social and health care system needs will become increasingly difficult. Unfortunately, a definite ante mortem diagnosis is not possible. Thus, an early diagnosis and identification of AD patients is critical for promising, early pharmacological interventions as well as addressing health care needs. The most advanced and most reliable markers are beta-amyloid, total tau and phosphorylated tau in cerebrospinal fluid (CSF). In blood, no single biomarker has been identified despite an intense search over the last decade. The most promising approaches consist of a combination of several blood-based markers increasing the reliability, sensitivity and specificity of the AD diagnosis. However, contradictory data make standardized testing methods in longitudinal and multi-center studies extremely difficult. In this review, we summarize a range of the most promising CSF and blood biomarkers for diagnosing AD. (C) 2011 Baishideng. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available